Vijay Balasubramanian, ATS 2022: An Interim Analysis of the EXPEDITE Study
We were delighted to speak to Dr. Vijay Balasubramanian (UCSF Fresno, Fresno, CA, USA) to learn more around the interim analysis of the EXPEDITE study (ClinicalTrials.gov Identifier: NCT03497689), which investigated whether a short course of parenteral treprostinil therapy would improve tolerability and dosing of oral treprostinil in patients with pulmonary arterial hypertension (PAH).
The abstract ‘Rapid Titration of Parenteral Treprostinil to EXPEDITE Dosing of Oral Treprostinil‘ (Abstract number: P203) was presented at ATS 2022, 13-18 May 2022.
- What has the EXPEDITE study taught us about the effectiveness of a short course of parenteral treprostinil therapy to improve tolerability and dosing of oral treprostinil in patients with PAH? (0:39)
- What were the aims of the interim analysis? (2:31)
- What different settings and routes of parenteral treprostinil were reported and which were preferred in the interim analysis? (4:34)
- What were your conclusions from the findings of the interim analysis? (6:38)
Disclosures: Vijay Balasubramanian discloses receiving grant/ research support from United Therapeutics and has participated in speaker’s bureaus for Bayer, Janssen, and Boehringer Ingelheim.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ATS meeting 2022.
Share this Video
Related Videos In Pulmonary Hypertension
Jean Elwing, CHEST 2022: Inhaled treprostinil for pulmonary hypertension due to interstitial lung disease – the INCREASE OLE study
INCREASE OLE was the open-label extension of the INCREASE study (NCT02630316), which investigated the safety and efficacy of inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease. We caught up with Prof. Jean Elwing (UC Health, Cincinnati, OH, USA) to discuss the methodology, inclusion criteria, and safety and tolerability findings from the […]
Marc Simon, CHEST 2022: Clinical benefits with a higher dose of LIQ861 in pulmonary arterial hypertension – analysis of the LTI-301 clinical trial
INSPIRE (LTI-301 clinical trial) was a phase 3 study investigating the long-term safety and tolerability of LIQ861 in patients with pulmonary arterial hypertension (NCT03399604). touchRESPIRATORY were delighted to talk with Dr. Marc Simon (UCSF Health, San Francisco, CA, USA) around the aims, design and eligibility criteria of the LTI-301 clinical trial and the findings from […]
Marc Simon, CHEST 2022: LIQ861 for the treatment of pulmonary arterial hypertension
LIQ861 is an investigational, inhaled dry powder formulation of treprostinil delivered through a device, which currently has tentative approval from the FDA for the treatment of pulmonary arterial hypertension (PAH). touchRESPIRATORY were delighted to talk with Dr. Marc Simon (UCSF Health, San Francisco, CA, USA) about LIQ861 and its potential advantages over conventional formulations of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!